By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Nov 19 (Reuters) - Pfizer (PFE.N), opens new tab and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded the state's Medicaid program over ...

Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk ...

The U.S. health regulator on Friday approved Innoviva's oral antibiotic to treat gonorrhea, a common sexually transmitted infection, offering patients an alternative to an injectable drug that was the ...